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http://dx.doi.org/10.1016/j.ccr.2012.07.024SUMMARYInitiation of pancreatic ductal adenocarcinoma (PDA) is definitively linked to activatingmutations in theKRAS
oncogene. However, PDA mouse models show that mutant Kras expression early in development gives rise
to a normal pancreas, with tumors forming only after a long latency or pancreatitis induction. Here, we show
that oncogenic KRAS upregulates endogenous EGFR expression and activation, the latter being dependent
on the EGFR ligand sheddase, ADAM17. Genetic ablation or pharmacological inhibition of EGFR or ADAM17
effectively eliminates KRAS-driven tumorigenesis in vivo. Without EGFR activity, active RAS levels are not
sufficient to induce robust MEK/ERK activity, a requirement for epithelial transformation.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is almost universally
fatal, but its remarkable genetic homogeneity has aided greatly
in our understanding of its genesis and progression. Most PDA
samples harbor oncogenic mutations in the KRAS gene, from
early pancreatic intraepithelial neoplasia (PanIN) to PDA,
marking mutant KRAS as the most prominent PDA initiating
gene. Pancreas-specific mutant Kras expression in mice results
in mouse PanIN (mPanIN) formation, eventually leading to PDA.
Strikingly, even with universal expression of mutant Kras in early
organogenesis, the pancreas develops normally, giving rise toSignificance
The almost universal lethality of PDA has led to the intense s
progression. Themost common oncogenic mutations associat
ing it as the primary initiator of pancreatic neoplasia. However
parenchyma shows that the oncogene remains largely indole
transforming potential.We findKRAS requires an inside-outsid
vation to initiate the signal transduction and cell biological cha
304 Cancer Cell 22, 304–317, September 11, 2012 ª2012 Elsevier Ina functional, tumor-free pancreas with preneoplastic lesions
and mPanINs forming stochastically only after several weeks
(Hingorani et al., 2003). Consistent with this, oncogenic KRAS
mutations are found in human pancreata with no signs of PDA
(Lu¨ttges et al., 1999). Together, these observations suggest
that expression of mutant Kras requires ill-defined secondary
events to initiate pancreatic tumorigenesis.
The ductal nature of PanIN and PDA suggests their derivation
via transformation of normal duct epithelium or of progenitor
cells capable of assuming a ductal morphology. Confounding
this hypothesis, KrasG12D expression directed to specific cellular
compartments has shown that duct, islet, and acinar cells can alltudy of genetic mutations responsible for its formation and
ed with all PDA stages are found in the KRAS gene, suggest-
, mutant Kras expression throughout the mouse pancreatic
nt until secondary events, such as pancreatitis, unlock its
e-in signaling axis that involves ligand-dependent EGFRacti-
nges that link PDA and pancreatitis.
c.
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EGFR Is Required for Pancreatic Tumorigenesisgive rise to mPanIN lesions (Gidekel Friedlander et al., 2009), but
expression in the adult acinar or islet cell compartments requires
pancreatitis induction (Carrie`re et al., 2009; Gidekel Friedlander
et al., 2009; Guerra et al., 2007). This acquired sensitivity to
transformation is attributed to acinar cell transdifferentiation to
metaplastic ducts, which have progenitor-like characteristics
(Miyamoto et al., 2003; Sharma et al., 1999) that may make
them more susceptible to KRAS-induced oncogenesis. Consis-
tent with this hypothesis, Hebrok and colleagues have shown
that KRASG12D expression hijacks the regeneration process after
tissue damage, promoting the metaplasia-to-PanIN transition
(Morris et al., 2010).
Aberrant signal transduction pathways that control acinar-
to-ductal metaplasia (ADM) are under intense study. Examina-
tion of chronic pancreatitis (CP) and PDA patient samples has
shown an upregulation of epidermal growth factor receptor
(EGFR, ERBB1) (Fja¨llskog et al., 2003; Korc et al., 1994; Tobita
et al., 2003) and several of its ligands (Kobrin et al., 1994; Zhu
et al., 2000). The relevance of this correlation is bolstered by
the induction of metaplasia and desmoplasia in vivo by trans-
genic EGFR ligand overexpression (Means et al., 2003; Sandg-
ren et al., 1990). In vitro, treatment of acinar cell explants with
EGFR ligands, such as transforming growth factor alpha
(TGFA), results in ADM (De Lisle and Logsdon, 1990; Means
et al., 2005). Lineage tracing experiments confirm that meta-
plastic ducts arise in part from acinar cell transdifferentiation in
response to tissue injury (Strobel et al., 2007), supporting a phys-
iological relevance to acinar cell transdifferentiation. However, it
is not known whether endogenous ligand activation of EGFR
plays a role in ADM in pancreatic disease.
Taking advantage of the reproducible kinetics of tumor forma-
tion in PDA mouse models, we set out to address the contribu-
tion of EGFR activity to disease progression using genetic and
pharmacological approaches.
RESULTS
EGFR Pathway Upregulation Precedes Tumorigenesis
in KrasG12D Mice
EGFR is upregulated in PDA and PDA mouse models (Fja¨llskog
et al., 2003; Korc et al., 1994; Tobita et al., 2003; Figure S1
available online), although its function primarily has been associ-
ated with enhanced proliferation and invasiveness (Jaganathan
et al., 2010; Larbouret et al., 2007; Pino et al., 2006; Zhao et al.,
2010). To better dissect the role of EGFR in PDA progression,
we tested if EGFR was activated in the KrasLSL-G12D/+;Ptf1aCre/+
mouse model (referred to hereinafter as KrasG12D), which repro-
ducibly shows metaplasia and mPanIN formation beginning at
8 weeks of age, with progression to PDA at 1 year (Hingorani
et al., 2003). Immunohistochemistry (IHC) for active EGFR
(pY1068) was undetectable in wild-type pancreata but easily
detectable in acinar areas prior to mPanIN formation in 30-day-
old KrasG12D mice and in mPanINs in 3-month-old KrasG12D
mice (Figure 1A). To test if EGFR itself was upregulated, we
used quantitative real-time PCR (qRT-PCR) to analyze mRNA
isolated from 6-week-old KrasG12D pancreata, an age prior to
the formation of significant metaplasia or neoplasia. Transcripts
for both EGFR and TGFA, an EGFR ligand, were consistently
upregulated 2-fold (Figure 1B). Amphiregulin (AREG), anotherCanEGFR ligand, was also upregulated relative to wild-type controls,
which had undetectable AREG levels (data not shown). Immuno-
fluorescence staining (IF) for total EGFR showed upregulation in
discrete acinar cell clusters in KrasG12D pancreata (Figure 1C),
becoming very prominent in larger acinar clusters, especially
near areas of metaplasia and mPanIN, and was particularly
high inmetaplasia andmPanINs. Thus, EGFRpathway upregula-
tion is a very early event in pancreatic tumorigenesis. Moreover,
the stochasticity of EGFRoverexpression in acini prior tomPanIN
formation reflected the pattern of eventual tumor formation,
suggesting a role for EGFR signaling in transformation of the
acinar cell compartment.
To test if acinar cell EGFR activation coincided with ductal
transdifferentiation, we examined primary acinar cell explants
isolated from KrasG12Dmice, which spontaneously transdifferen-
tiate into duct cells when embedded in fibrillar collagen. On Day
1 of culture, active pY1068 EGFR was undetectable (Figure 1D)
but was strongly positive by Day 3, as transdifferentiation took
place. Activation correlated with increased EGFR expression,
as determined by qRT-PCR (Figure 1E). Thus, EGFR upregula-
tion and activation is initiated by KRAS in vitro and in vivo in
a manner consistent with its involvement in preneoplastic duct
formation.
Inhibition of EGFR Limits Pancreatic Tumorigenesis but
Not Progression
To test if EGFR activity is required for pancreatic preneo-
plastic lesion formation, we examined the effects of pharmaco-
logical EGFR inhibition in a highly aggressive PDA model.
KrasLSL-G12D/+;Ptf1aCre/+;Trp53fl/fl mice, referred to as KrasG12D;
p53KO, develop invasive PDA at 4–6 weeks of age (Bardeesy
et al., 2006). Starting at 1 week of age, KrasG12D;p53KO mice
were treated daily with either cetuximab, a monoclonal antibody
that blocks ligand interaction with the receptor; erlotinib, a small
molecule EGFR tyrosine kinase inhibitor; or vehicle for 3 weeks.
Histological examination showed substantial areas of normal,
nontransformed tissue with either treatment, and a significantly
reduced number of CK19+ ductal lesions compared to control
(Figures 2A–2C).
Retention of substantial areas of normal tissue with EGFR
inhibition supported a role for EGFR signaling in tumor initiation.
To test this possibility definitively, we mated KrasG12D;p53KO
mice with conditional Egfr knockout mice (Lee and Threadgill,
2009; Natarajan et al., 2007). Mice with EGFR ablated from the
pancreas (Egfrfl/fl;Ptf1aCre/+, referred to as EgfrKO) were viable
and showed no gross pancreatic abnormalities. Consistent
with the inhibitor experiments,KrasG12D;p53KO;EgfrKO pancreata
retained substantial areas of normal acinar tissue, whereas age-
matched KrasG12D;p53KO pancreata were completely replaced
by tumorous tissue (Figures 2D and 2E). IHC for EGFR confirmed
that 50% of mPanINs that formed in these mice were EGFR
negative (Figure S2A), with the other half likely a product of
incomplete recombination of the Egfr locus. To gain insight
into the escape from EGFR dependency, we established cell
lines from KrasG12D;p53KO;EgfrKO pancreata. Confirming EGFR
loss by western blot, we assessed other signaling and differenti-
ation changes compared to EGFR wild-type controls. Two path-
ways in particular showed consistent upregulation and activation
in the absence of EGFR: the Notch pathway and MET, both ofcer Cell 22, 304–317, September 11, 2012 ª2012 Elsevier Inc. 305
Figure 1. EGFR Signaling during mPanIN Development
(A) IHC for EGFR pY1068 in wild-type and KrasG12D pancreata. Scale bars, 50 mm.
(B) qRT-PCR analysis for Egfr, its ligands, and Adam17. Error bars, ± SEM. *p < 0.05, n = 3.
(C) Confocal IF staining for total EGFR in distinct single acinar cells, acinar cell clusters (asterisk), ADM (arrow), and mPanINs (arrowhead) of KrasG12D pancreata.
Scale bars, 10 mm.
(D and E) Panels show (D) IF for EGFR pY1068 and (E) qRT-PCR analysis of Egfr in KrasG12D acinar cell explants. Scale bars, 10 mm for micrographs, 50 mm for
inset. Error bars, ±SEM; *p < 0.05, n = 3.
See also Figure S1.
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EGFR Is Required for Pancreatic Tumorigenesiswhich have been implicated in pancreatic tumor progression
(Figure S2B), most notably in the ADM process (Means et al.,
2005; Miyamoto et al., 2003).
EGFR inhibition has been shown to be minimally effective in
PDA patients. To test if the KrasG12D;p53KO model reflected the
clinical data, we treated mice with magnetic resonance imaging
(MRI)-detectable advanced PDA with gemcitabine or erlotinib
plus gemcitabine. Combination-treated mice showed no signifi-
cant difference in life span compared to mice with gemcitabine
treatment alone (Figure 2F) and showed no reduction in tumor
burden by MRI, consistent with independence from EGFR after
progression to PDA.
EGFR inhibition most clearly affected pancreatic tumori-
genesis, leading us to explore its effects more thoroughly in
the slower-progressing KrasLSL-G12D/+ model. Tumor burden of306 Cancer Cell 22, 304–317, September 11, 2012 ª2012 Elsevier InKrasG12D and Egfr knockout KrasG12D mice (KrasG12D;EgfrKO)
was assessed at various ages by relative pancreatic mass,
histology, loss of normal acinar (amylase+) tissue, and appear-
ance of MUC5AC+ ductal lesions (Figures 3A–3C, S3A, and
S3B). By all criteria, Egfr ablation almost completely blocked
tumorigenesis. Unlike KrasG12D;p53KO;EgfrRKO mice, all meta-
plasia and mPanIN that formed in KrasG12D;EgfrKO mice were
EGFR positive (Figure S3D), suggesting incomplete recombina-
tion of the Egfr locus and reinforcing the need for EGFR in tumor-
igenesis. These data also suggested that p53 inactivation itself
allows for escape from EGFR dependency. The tumorigenesis
blockwas not due to a failure to recombine the silencedKrasG12D
allele (Figure S3E).
Coordinated upregulation of Tgfa, Areg, and Egfr in KrasG12D
pancreata, together with the effectiveness of cetuximab,c.
Figure 2. Inhibition of EGFR Signaling
Blocks KRAS-Driven Tumorigenesis but
Not PDA Progression
(A) Hematoxylin and eosin staining (H&E) and
CK19 IHC of 4-week-old KrasG12D;p53KO control,
cetuximab-treated, and erlotinib-treated pan-
creata. Arrowheads indicate CK19+ structures.
Scale bars, 100 mm for H&E and 50 mm for CK19
panels.
(B) Schematic of cetuximab and erlotinib treat-
ment protocols.
(C) Quantitation of CK19+ structures (n = 3; **p <
0.01; ***p < 0.001).
(D) Histology of 9-week-old KrasG12D;p53KO and
KrasG12D;p53KO;EgfrKO pancreata. Asterisks indi-
cate areas of invasive PDA. Arrowheads highlight
areas of normal acinar tissue. Scale bars, 200 mm
for upper panels and 50 mm for lower panels.
(E) Quantitation of normal acinar area in KrasG12D;
p53KO and KrasG12D;p53KO;EgfrKO pancreata.
(F) Kaplan–Meier curve depicting survival of
KrasG12D;p53KO mice treated with gemcitabine
or erlotinib plus gemcitabine after progression
to PDA.
See also Figure S2.
Cancer Cell
EGFR Is Required for Pancreatic Tumorigenesissuggested that receptor ligation is a necessary step in pancre-
atic tumorigenesis. EGFR ligands are generally shed from
the cell surface by metalloproteinase ‘‘sheddases’’ but can
also activate receptor in their membrane-bound forms in a
juxtacrine manner (Singh and Harris, 2005). TGFA and AREG
share a common primary sheddase in ADAM17 (Sahin et al.,
2004). To test if EGFR ligand shedding was necessary for
tumorigenesis, we crossed a conditional Adam17 knockout
mouse line (Adam17DEx5/DEx5) into the KrasG12D background
(KrasG12D;Adam17KO). Pancreas-specific Adam17 knockoutCancer Cell 22, 304–317, Semice (Adam17DEx5/DEx5;Ptf1aCre/+, re-
ferred to as Adam17KO) were viable
and showed no gross pancreatic abnor-
malities. To assess tumor formation in
the KrasG12D;Adam17KO background,
we aged mice and examined their pan-
creata for tumor development. Indeed,
KrasG12D;Adam17KO mice phenocopied
KrasG12D;EgfrKO mice, showing a similar
degree of protection from tumorigenesis
(Figures 3A–3C, S3A, and S3C), with no
effect on KrasG12D recombination (Fig-
ure S3E). These results are consistent
with EGFR activation by ADAM17-
dependent ligand shedding being a





Oncogenic Kras expression confined
to acinar or islet cell compartments,
requires pancreatitis for PDA formation(Gidekel Friedlander et al., 2009; Guerra et al., 2007). EGFR over-
expression in KrasG12D acinar cells suggested that EGFR abla-
tion blocks transformation of this cellular compartment. To test
if EGFR activity is required for pancreatitis-dependent, acinar
cell-derived tumorigenesis, we treated 30-day-old KrasG12D,
KrasG12D;EgfrKO, and KrasG12D;Adam17KO mice with 250 mg/kg
cerulein, a known inducer of pancreatic damage, daily for
5 days, followed by 7 days recovery. With cerulein treatment,
KrasG12D mice showed an almost complete replacement of
normal pancreatic tissue with fibrotic, inflamed tissue and theptember 11, 2012 ª2012 Elsevier Inc. 307
Figure 3. Genetic Ablation of EGFR Activity Prevents KRAS-Driven PDA Development
(A–G) Panels show (A–C) spontaneous and (D–G) cerulein-induced mPanIN formation in KrasG12D;EgfrKO and KrasG12D;Adam17KO mice compared to KrasG12D
controls, shown by H&E (left panels; scale bars, 200 mm) and dual IHC for CK19 (brown) and amylase (blue) (right panels; scale bars, 100 mm). Quantitation of
pancreas-to-body weight ratios in (B) and (F) and amylase-positive area in (C) and (G) (n > 6; **p < 0.01; ***p < 0.001) compared to control.
Cancer Cell
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EGFR Is Required for Pancreatic Tumorigenesismajority of epithelia replaced by metaplasia and mPanIN. Both
KrasG12D;EgfrKO and KrasG12D;Adam17KO mice were almost
completely protected from this dramatic transition (Figures
3D–3G).
Noting the earlier correlation between the patterns of EGFR
overexpression and spontaneous tumor formation, we tested if
cerulein treatment affected EGFR expression. Using a truncated
cerulein treatment protocol (Figure 3H), we examined EGFR
expression prior to rampant epithelial morphogenesis (Figure 3I).
In 34-day-old saline-treated controls, EGFR was minimally ex-
pressed in wild-type pancreata. As noted previously, in KrasG12D
controls, EGFR was elevated in discrete acinar clusters (1.3% of
acinar cells). In contrast, 3 days of cerulein treatment in wild-type
mice induced EGFR in discrete acini (<1% of total) after 1 day
recovery, which returned to baseline levels with 3 days recovery.
It is striking that cerulein treatment of KrasG12D mice induced
very high EGFR expression in 73% of acinar cells with 1 day
recovery, which was sustained after 3 days recovery and ele-
vated further in metaplasia that had begun to form. Once again,
EGFR overexpression in acinar cells reflected the pattern of the
eventual tumor formation in this model.
The striking upregulation of EGFR in acinar cells suggested
that this cellular compartment is prominently affected by its
activity. Besides inducing acinar cell transdifferentiation, EGFR
is known to both protect cells from apoptotic cell death and to
induce proliferation. Cleaved caspase-3 IHC showed no signifi-
cant upregulation of apoptosis in 6-week-old KrasG12D pan-
creata (data not shown). In contrast, proliferation, as measured
by BrdU incorporation, increased 4-fold in KrasG12D acinar
cells compared to wild-type, with this increase reduced by half
in KrasG12D;EgfrKO acinar cells (Figures 3J and 3K). This differ-
ence was exaggerated in cerulein-treated mice, where >10%
of acinar cells in KrasG12D mice incorporated BrdU, with no
increase under the same conditions in KrasG12D;EgfrKO pan-
creata. Consistent with this, CyclinD1 was upregulated in acinar
cells of KrasG12D and cerulein-treated KrasG12D mice but re-
mained unchanged in KrasG12D;EgfrKO pancreata with or without
cerulein (Figures 3L and 3M).
EGFR Activity Is Required for Metaplastic Duct
Formation
The dependency of acinar-cell-derived pancreatic tumorigen-
esis on pancreatitis has been attributed to the need for ADMprior
to transformation (Gidekel Friedlander et al., 2009). Chronic acti-
vation of EGFR is sufficient to induce ADM in vitro (De Lisle and
Logsdon, 1990) and in vivo (Sandgren et al., 1990). To test if
EGFR signaling is necessary for this process, we used several
in vivo and in vitro models of ADM. Chronic overexpression of(H) Truncated cerulein treatment protocol for analysis of premetaplastic signaling
(I) EGFR IHC in saline-treated (control) and cerulein treatedWT (left panels) and Kr
focal areas of high EGFR expression. n = 3, scale bars = 20 mm.
(J) BrdU incorporationmeasured by IHC in acinar cells of saline or cerulein-treated
positive acinar nuclei. Scale bar, 20 mm.
(K) Counts of BrdU+ acinar cells; n = 3; **p < 0.01.
(L) Co-IF for CyclinD1 (green) and EGFR (red) in saline or cerulein-treated KrasG
bar, 10 mm.
(M) Quantitation of CyclinD1 expression. *p < 0.05; ***p < 0.001; all other differen
Error bars in all panels, ± SEM. See also Figure S3.
Canthe EGFR ligand TGFA in the Ela-Tgfa transgenic model induces
substantial ductal metaplasia and fibrosis after several weeks of
transgene expression (Sandgren et al., 1990). Ablation of either
Egfr or Adam17 effectively eliminated TGFA-induced metaplasia
in vivo even at 1 year of age (Figure S3F), reinforcing the neces-
sity for ligand shedding in the ADM process.
Turning to metaplasia associated with experimental pancrea-
titis, we used a cerulein treatment protocol that produced a
chronic pancreatitis-like phenotype in wild-type mice, marked
by replacement of acinar tissue with metaplastic ducts and
a reactive and inflamed stroma (Figure S3G). Both EgfrKO and
Adam17KO mice were strongly protected from most aspects of
pancreatitis, including ADM and the parallel stromal response.
Quantitation of inflammatory cell infiltration into the damaged
tissue confirmed a significant loss of this response (Figures
S3H and S3I). Protein arrays revealed that several cytokines
were significantly lower in cerulein-treated EgfrKO pancreata
compared to wild-type, including RANTES, IL16, CXCL13, and
IL23 (data not shown). However, the common expression of
each of these factors by reactive inflammatory and other
stromal cells suggested that these lower levels were possibly
a secondary effect of the reduction in inflammatory infiltrates.
Two proinflammatory proteins that were definitively produced
by the metaplastic epithelia, as well as the stroma, were
COX-1 and COX-2 (Figure S3J), suggesting that the inability of
EgfrKO pancreata to form metaplastic ducts contributes to the
reduced inflammatory response.
The block in the pancreatitis phenotype was not due to
gross loss of cerulein-induced signal transduction. When
treated with cerulein to induce acute pancreatitis, mice of all
genotypes showed a gain of pancreatic wet weight associated
with edema, increased serum amylase levels, areas of tissue
necrosis, and induction of acinar cell SOX9 expression (Figures
S3K–S3N).
We then tested if in vitro ADM required EGFR activation.
In vitro ADM in collagen-embedded acinar cell explants is usually
induced by the addition of ectopic EGFR ligand. To simulate the
in vivo animal models more closely, and to bypass direct EGFR
stimulation, we chose to induce in vitro ADM either by expres-
sion of KrasG12D or by addition of low concentrations of cerulein
into the culture medium.
Acinar cell explants derived from KrasG12Dmice transdifferen-
tiated spontaneously in culture within 3 days, as determined by
coimmunofluorescence for the acinar and duct cell markers,
amylase and CK19, respectively. This transition was almost
entirely absent in explants derived from KrasG12D;EgfrKO mice
(Figures 4A and 4B), arresting at a nestin-positive intermediate
stage (Miyamoto et al., 2003) (Figures S4A and S4B)..
asG12D (right panels) pancreata with 1 day and 3 days recovery. Arrows indicate
KrasG12D andKrasG12D;EgfrKO pancreata with 3 days recovery. Arrows indicate
12D and KrasG12D;EgfrKO. Arrows indicate some positive acinar nuclei. Scale
ces were not significant, n = 3.
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Figure 4. EGFR Signaling Is Required for
Acinar Transdifferentiation in Three-Dimen-
sional Primary Culture
(A) Light microscopy (left panels) and co-IF for
amylase (green) and CK19 (red, right panels) in
KrasG12D and KrasG12D;EgfrKO acinar cell explants
after 3 days in three-dimensional collagen culture.
Arrowhead indicates area of ductal morphology
in KrasG12D explants, compared to maintained
acinar cell morphology and amylase expression in
KrasG12D;EgfrKO explants (arrows). Scale bars,
20 mm.
(B) Quantitation of amylase and CK19 positive
acinar clusters on Day 3 of culture.
(C) Co-IF for amylase (green) and CK19 (red) in
cerulein-treated WT (left panels), EgfrKO (middle
panels), and Adam17KO acinar cell explants (right
panels). Arrowheads indicate CK19+ cells. Scale
bars, 20 mm.
(D) Quantitation of amylase and CK19 posi-
tive acinar clusters in cerulein-treated explant
cultures.
See also Figure S4.
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with cerulein induced ADMwithin 5 days (Figure 4C). Both EgfrKO
and Adam17KO explants were strongly resistant to this effect,
although EgfrKO explantsweremore so (Figures 4C and 4D), indi-
cating possible compensation from other sheddases. Like
KRASG12D (Figure 1C), cerulein also induced EGFR activation,
in an ADAM17-dependent manner (Figure S4C). We then exam-
ined expression of the EGFR ligands and ADAM17 substrates
TGFA and AREG in acinar explants. While AREG was not de-
tected (data not shown), TGFA was induced by the third day of
cerulein treatment (Figure S4D), independent of genotype, con-
firming that the mutant acinar cells remain cerulein responsive.
Finally, because ADAM17 is known to shed several bioactive
cell surface molecules, we confirmed that the Adam17KO ADM
blockade did not require shedding of other substrates by
rescuing the wild-type phenotype with addition of TGFA to the
culture medium (Figure S4E).
The dependency of pancreatitis-associated and in vitro ADM
upon acinar cell EGFR and ADAM17 led us to test the relevance
of these findings to human disease. Expression of components
of the EGFR pathway in human CP, including active EGFR
(pY1068), ADAM17, TGFA, and AREG was determined by
IHC (Figure S4F). Regardless of CP type (alcoholic, familial, or
spontaneous), active EGFR, ADAM17, and TGFA were consis-
tently upregulated, particularly in acinar cells adjacent to in-
flamed and fibrotic stroma in 10/10 CP samples. AREG was
consistently expressed in ductal metaplasia adjacent to nonex-
pressing acinar cells. Thus, activation of the EGFR circuitry
in vivo and in vitro is reflected in human CP.310 Cancer Cell 22, 304–317, September 11, 2012 ª2012 Elsevier Inc.EGFR-Dependent ERK Activation Is
Required for Pancreatic
Tumorigenesis
Initially, we hypothesized that EGFR was
responsible for activation of some of the
pathways that have been shown to be
important for pancreatic tumorigenesis,including STAT3 and RAC1. Contrary to these possibilities, we
observed substantial pSTAT3 in KrasG12D;EgfrKO pancreata
comparable to KrasG12D tissue (Figure S5A). We also saw no
change in active RAC pulldown experiments (data not shown).
Recent data suggesting that RAS activation must reach
a minimum threshold in order to transform the pancreas (Ji
et al., 2009) led us to examine if EGFR and ADAM17 inhibition
or ablation is consistent with this model by examining down-
stream effectors of RAS, including PI3K/AKT (pAKT) and
MAPK (pERK1/2). KrasG12D;EgfrKO mice showed no diminution
of active AKT compared to control KrasG12D mice (Figure 5A),
suggesting no difference in PI3K activity. In contrast, we
observed2-fold lower levels of pERK in 3-month-old KrasG12D;
EgfrKO pancreatic lysates (Figure 5A). Since this difference
may be an indirect effect of enhanced pERK levels in tumors
that form only in KrasG12D controls, we confirmed a similar loss
of pERK in 4-week-old pancreatic lysates prior to substantial
transformation (Figure 5A, lower panel). IHC for pERK in
4-week-old KrasG12D mice revealed several positive isolated
acinar regions (0.8% of total), whereas in KrasG12D;EgfrKO
mice, pERK was limited to stromal cells (Figure 5B). ERK activa-
tion was also clearly detectable in 88% of acinar cell clusters in
wild-type cerulein-treated acinar explants, compared to 4.2%
and 10.8% in EgfrKO and Adam17KO explants, respectively
(Figure 5C).
KRAS oncogenic mutations are dominant, usually only affect-
ing a single allele. Thus, approximately half the KRAS protein ex-
pressed is wild-type and turns over guanosine triphosphate
(GTP) at a rapid rate, thus inactivating signaling. Active EGFR
Cancer Cell
EGFR Is Required for Pancreatic Tumorigenesisis known to relocalize wild-type KRAS to the plasma membrane
via Grb2/Sos where it is activated (Basu et al., 1994; Gale
et al., 1993). Consistent with this, coimmunoprecipitation and
coimmunofluorescence experiments showed clear interaction
and colocalization of KRAS and EGFR in KrasG12D-expressing
tumor cell lines and acinar explants (Figures S5B and S5C).
Using isolated acinar cells from wild-type, KrasG12D, KrasG12D;
EgfrKO and KrasG12D;ADAM17KO mice, we found an upregula-
tion of both total and active RAS in KrasG12D acinar cells
(Figure 5D), consistent with previous reports (Ji et al., 2009).
However, in KrasG12D;EgfrKO and KrasG12D;ADAM17KO cells,
active RAS was reduced by more than 50%, while the upregu-
lation of total RAS remained, leaving the active/total RAS
ratios an average of 55% and 45% lower than KrasG12D cells,
respectively.
We next tested if EGFR activity was required for maintenance
of ERK activity when Kras is mutated. Treatment of isolated
KrasG12D acinar cells with erlotinib reduced the active RAS/total
RAS ratio by an average of 39.8% compared to control, with no
effect on total RAS expression (Figure 5E). We then treated
KrasG12D mice with cerulein to induce rampant transformation
(Figure 3D) then treated acutely with erlotinib by oral gavage
12, 6, and 2 hr prior to tissue harvest. Compared to vehicle, erlo-
tinib treatment reduced pERK levels by an average of 46% (Fig-
ure 5F). Treated pancreata showed an obvious reduction of
pERK IHC, especially in isolated mPanINs (Figure 5G). Unlike
our observations in EgfrKO mice, acute erlotinib treatment
dramatically reduced pAKT staining in mPanINs (Figure 5G),
suggesting an acute effect on PI3K signaling that is apparently
compensated for under conditions of chronic inhibition. Con-
sistent with the knockout mice, no alteration in pSTAT3 was
observed (Figure 5G). Erlotinib-treated pancreata also showed
a dramatic4-fold upregulation of cleaved caspase-3 IHC-posi-
tive cells (Figure 5H) and a significant decrease in CyclinD1
expression (Figure 5I), indicating that EGFR activity is critical
for survival and proliferation of metaplastic and mPanIN epi-
thelia. EGFR dependency is also demonstrable in human PDA
cell lines, with both RAS and ERK activity responsive to EGFR
inhibition and activation, even inKRASmutant cells (Figure S5D).
We also found upregulation of pERK IHC in acinar cells of human
CP samples (Figure S5E), consistent with a role in ADM in human
disease.
We have shown that EGFR is required for ADM and ERK
activation and that EGFR and pERK are upregulated in acinar
cells in human CP. To test if ERK activation is involved in ADM
in vitro and pancreatic tumorigenesis in vivo, we used the allo-
steric MEK1/2 inhibitor BAY 86-9766 (Iverson et al., 2009).
BAY 86-9766 treatment of KrasG12D acinar explants strongly
blocked transdifferentiation (Figures 6A and 6B).We then treated
6-week-old KrasG12D mice with cerulein to induce pancreatitis.
Concomitant with pancreatitis induction and continuing for
3 weeks after, mice were treated daily with 25 mg/kg BAY86-
9766 or vehicle by oral gavage (Figure 6C). As expected, pERK
levels in BAY86-9766-treated pancreata were reduced (Fig-
ure 6D) and vehicle-treated KrasG12D mice developed fibrotic,
inflamed tissue, with the majority of epithelia replaced by meta-
plasia and mPanIN. In contrast, BAY86-9766-treated mice
retained mostly phenotypically normal tissue with only rare
MUC5AC+ mPanINs (Figures 6E and 6F).CanDISCUSSION
The reproducible tumor onset and progression in the KrasG12D
PDAmodel has allowed us to explore howEGFR affects the tran-
sition of normal epithelia to neoplastic lesions.We find that KRAS
upregulates EGFR in distinct, phenotypically normal acinar clus-
ters prior to formation of metaplasia and mPanINs. Acinar cell
upregulation of EGFR is rapid in cerulein-induced pancreatitis,
with KRASG12D activity able to sustain the elevated expression.
Most important, blocking EGFR activity effectively eliminates
KRAS-initiated pancreatic tumorigenesis, with or without pan-
creatitis induction, due to its critical role in amplifying ERK acti-
vation within the pancreas. Furthermore, EGFR is critical for
acinar cell proliferation and its stimulation of MEK is necessary
for transdifferentiation of transformation-resistant acinar cells
to a transformation-sensitive, progenitor cell-like, metaplastic
duct cell. Thus, we propose that EGFR’s major role in pancreatic
tumorigenesis lies in its control of the differentiation of neoplastic
precursors and, after tumor initiation, maintenance of ERK
activity.
EGFR has been implicated in the pathogenesis of several
epithelial cancers (Normanno et al., 2006). Inappropriate EGFR
activation results from mutation of the receptor or overexpres-
sion of its ligands and their ADAM sheddases. Its contributions
in RAS-mutated tumors are presumed to be through activation
of complementary oncogenic pathways, as its abilities to acti-
vate the RAS pathway would be redundant. Nonetheless, upre-
gulation of EGFR, its ligands, and ADAM17 have been reported
in PDA (Friess et al., 1996; Ringel et al., 2006), consistent with
their importance in these usually Kras mutant cancers. Several
studies show that constitutive RAS signaling is not sufficient to
compensate for EGFR activity. EGFR is necessary for the growth
(Dlugosz et al., 1997) and survival (Sibilia et al., 2000) of RAS-
initiated cutaneous squamous cell carcinoma and maintains
the stem-cell-like nature of transformed keratinocytes (Hansen
et al., 2000). In H-RAS initiated melanoma, an EGFR autocrine
loop is required for tumor cell maintenance and survival
(Bardeesy et al., 2005). In PDA cell lines, the unique activities
of EGFR promote cell proliferation and invasion even when
KRAS is mutated (Jaganathan et al., 2010; Larbouret et al.,
2007; Pino et al., 2006; Zhao et al., 2010). Overall, the majority
of studies support models where EGFR in RAS-mutated tumors
is generally involved in posttransformation functions. Two
studies provide notable exceptions where, in vitro, RAS transfor-
mation of otherwise normal immortalized cells requires EGFR
activity (Gangarosa et al., 1997; Sibilia et al., 2000). In addition,
concomitant pancreatic activation of oncogenic KRAS and
EGFR signaling leads to accelerated formation of high-grade
preneoplastic lesions and PDA (Siveke et al., 2007). Our data
support a model where endogenous EGFR signaling is required
to maintain the critical threshold of RAS activity required for
tumorigenesis (Ji et al., 2009). Based on numerous experimental
approaches, loss of EGFR signaling resulted in an50% drop in
active RAS, consistent with continual stimulation of GTP loading
of the highly catalytically active wild-type RAS proteins, although
we cannot eliminate the possibility that it is required for the occa-
sional reactivation of the catalytically impaired mutant KRAS.
Much has been made recently of experimental pancreatitis
being required for transformation of oncogenic KRAS expressingcer Cell 22, 304–317, September 11, 2012 ª2012 Elsevier Inc. 311
Figure 5. Endogenous EGFR Is Required for Robust Activation of RAS and ERK
(A) Western blot analysis of whole pancreatic lysates for active pAKT and pERK in KrasG12D and KrasG12D;EgfrKOmice, at 3 months (upper andmiddle panels) and
pERK at 1month of age (lower panels). Numbers indicate densitometric quantitation of pERK/total ERK and pAKT/AKT ratios of representative blots shown; n = 4.
(B) IHC for active pERK in 6-week-old KrasG12D and KrasG12D;EgfrKO pancreata. Arrows indicate areas of focal acinar cell staining. Metaplasia is indicated with an
M. Arrowheads indicate stromal cell staining. Micrographs are representative of six mice. Scale bar, 20 mm.
(C) IF staining for active pERK in acinar cell explants of cerulein treated wild-type (WT), EgfrKO, and Adam17KO explants at 0 and 3 days of culture. Arrows indicate
areas of positive staining. Scale bar, 20 mm.
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Guerra et al., 2007, 2011). In this model, cerulein induces intra-
cellular activation of digestive enzymes, leading to cellular stress
and necrosis. Necrosis attracts inflammatory cells, which coop-
erate with oncogenic KRAS in the epithelia to induce tumor
formation by overcoming cellular senescence (Guerra et al.,
2011; Lee and Bar-Sagi, 2010). While this provides a satisfying
connection between PDA and one of its primary risk factors,
our data show that KRAS and cerulein induce transdifferentia-
tion of acinar cells in vitro by inducing EGFR expression and
ADAM17-dependent activation, demonstrating that the earliest
steps in this program are initiated cell autonomously. Even so,
since parenchymal EGFR ablation also dampens the stromal
response, definitive separation of epithelial and stromal contri-
butions to tumorigenesis is complicated. EGFR is known to influ-
ence the expression of inflammatory cytokines (Mascia et al.,
2010; Monick et al., 2005), and expression of the proinflamma-
tory COX proteins in metaplastic ducts suggests that reactive
epithelia promote the host response. Unlike EGFR or pERK
activity, however, we did not find COX upregulation in acinar
cells, suggesting that this is not direct control of gene expression
by EGFR signaling but is inherent to the metaplastic duct
phenotype.
The role of EGFR as a therapeutic target in PDA is complex. In
unselectedmetastatic PDA patients, anti-EGFR therapy has only
a modest survival effect; however, subgroups of patients and
defined molecular subtypes respond to EGFR targeting (Collis-
son et al., 2011; Jimeno et al., 2008; Moore et al., 2007). In our
study, EGFR-negative PDA developed in KrasG12D;p53KO;EgfrKO
mice, albeit with reduced efficiency. In addition, KrasG12D;
p53KOmice showed no additional survival advantage with erloti-
nib treatment, indicating that development and progression to
PDA can be EGFR independent in a p53 null setting. While we
have some indication of what may be compensating for EGFR
loss, such as MET activation, this activity was detectable in
only a minority of EGFR negative tumors, possibly suggesting
multiple routes for bypassing EGFR deficiency. Defining the
underlying molecular cues and defining the role of p53 inactiva-
tion as a potential contraindication of responsiveness to EGFR
inhibition are important issues to be resolved.
In summary, we have identified a critical role for EGFR in
KRAS’s reprogramming of the pancreatic epithelia en route
to tumorigenesis. EGFR activation in this context requires
ADAM17 and results in a substantial amplification of MEK sig-
naling. The ADAM17/EGFR/MEK signaling axis is critical for
some of the fundamental pathologies associated with PDA
risk, such as formation of metaplastic ducts in pancreatitis, sug-(D) Active RAS pulldown assays from lysates of isolated primary acinar cells fr
indicate densitometric quantitation of the ratio of GTP-bound and total RAS of rep
(pERK/ERK) in these lysates; n = 3.
(E) GTP-bound RAS/total RAS and pERK/total ERK ratios in isolated acinar cells
blots shown. n = 3.
(F) KrasG12D mice were treated with cerulein as in Figure 3D to induce uniform tum
before sacrifice. Shown are western blots of pY1068 and total EGFR and pERK
(G) IHC for active pERK, pAKT, and pSTAT3 in vehicle or erlotinib-treated mice de
(H and I) IHC and quantitation for (H) cleaved caspase-3 (CC3) and (I) CyclinD1
bars, ± SEM.
See also Figure S5.
Cangesting that there may be benefit in targeting the pathway in
these at-risk patients to restore homeostasis and thereby reduce
the chance of tumorigenesis.
EXPERIMENTAL PROCEDURES
Mice
KrasLSL-G12D/+, Ptf1aCre/+, Ela-Tgfa, Trp53fl/fl, Adam17DEx5/DEx5, and Egfrfl/fl
strains have been described elsewhere (Hingorani et al., 2003; Kawaguchi
et al., 2002; Lee and Threadgill, 2009; Marino et al., 2000; Natarajan et al.,
2007; Sandgren et al., 1990; Siveke et al., 2007; Tang et al., 2011). Experiments
were conducted in accordance with the Office of Laboratory Animal Welfare
and the German Federal Animal Protection Laws and were approved by the
Institutional Animal Care and Use Committees of the Technische Universita¨t
Mu¨nchen, Stony Brook University, and the Mayo Clinic.
Histology, IHC, IF, and Western Blot
Distribution and the use of all human samples were approved by the Institu-
tional Review Boards of Vanderbilt University Medical Center and the Mayo
Clinic. IHC was performed on a Ventana XT (Tucson, AZ, USA) autostainer
or as previously described (Siveke et al., 2007). For total EGFR and phos-
pho-ERK IHC, mice were anesthetized and perfused with 4% paraformalde-
hyde. All IHC was counterstained with hematoxylin except amylase/CK19
dual IHC. Quantitation of amylase-positive area was performed on singly
DAB-stained sections using Olympus cellSens Dimension software. Quantita-
tion represents the average of 15–20 203 fields of view from three mice of
each genotype, treatment regimen, or time point, as indicated. IF and western
blot were performed according to standard protocols (Siveke et al., 2007).
Confocal IF images were collected on a Leica SP2 or a Ziess-LSM-510 Meta
confocal microscope at consistent gain and offset. Antibodies are described
in the Supplemental Experimental Procedures.
RAS Activity Assay
GST-Raf-1-RBD fusion protein was prepared by modifying procedures pub-
lished elsewhere (Castro et al., 2005). Details of cell preparation and protocol
modifications are found in the Supplemental Experimental Procedures.
Quantitative RT-PCR
RT-PCR was performed as previously described (Siveke et al., 2007). For
protocol details, see the Supplemental Experimental Procedures.
Preparation of Pancreatic Epithelial Explants Culture
Pancreatic epithelial explants were as described previously (Heid et al., 2011).
Either recombinant human TGF-a (rh TGFa, R&D Systems; final concentration,
50 ng/ml) or cerulein (American Peptide Company; final concentration, 2.6 pM)
was added as indicated. For MEK inhibition, BAY 86-9766 (provided by Bayer
Schering) was added at indicated concentrations.
For each genotype, experiments with acinar epithelial explants were per-
formed with the following numbers of mice: WT, n = 15; EgfrKO, n = 5;
Adam17KO, n = 10; KrasG12D, n = 7; KrasG12D;EgfrKO, n = 10; WT plus BAY
86-9766, n = 3; and KrasG12D plus BAY 86-9766, n = 3. For quantification,
acinar explants were seeded in triplicate and cell clusters were counted
from at least three optical fields per well.om WT, KrasG12D, KrasG12D;EgfrKO, and KrasG12D;Adam17KO mice. Numbers
resentative blots shown. Western blots show concomitant relative ERK activity
treated with erlotinib for 6 hr. Numbers indicate quantitation of representative
origenesis and then treated with vehicle or 100 mg/kg erlotinib 12, 6, and 2 hr
and total ERK. Numbers indicate ratios of representative blots shown; n = 3.
scribed in (F). Scale bar, 100 mm for primary micrographs and 50 mm for insets.
in vehicle or erlotinib-treated mice described in (F). Scale bars, 50 mm. Error
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Figure 6. ERK Activity Is Critical for Metaplasia and Neoplasia
(A) Co-IF for amylase and CK19 in acinar cell explants of KrasG12Dmice treated with either the MEK inhibitor BAY 86-9766 or vehicle. Arrowheads point to CK19+
duct-like structures. Scale bar, 20 mm.
(B) Quantitation of amylase+ and CK19+ cell clusters is representative of at least three independent experiments per treatment.
(C) Schematic illustration of pancreatitis induction in KrasG12D mice with a BAY 86-9766 treatment regimen. In 6-week-old KrasG12D mice pancreatitis was
induced by six hourly injections with 50 mg/kg cerulein on 2 consecutive days. Mice were treated either with a daily oral dose of BAY 86-9766 or vehicle, 6 days/
week for 3 consecutive weeks, beginning on the first day of cerulein treatment.
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To induce a CP-like phenotype, 250 mg/kg cerulein injections twice daily were
administered intraperitoneally (i.p.) for 3 weeks, with 24 hr recovery. KrasG12D
and knockout derivatives were treated with 250 mg/kg cerulein once daily for 5
consecutive days and allowed to recover for 1 week before tissue harvesting.
For examining EGFR protein induction, one daily 250 mg/kg dose was admin-
istered i.p. for 3 days, with 1 or 3 days of recovery, as indicated.
In Vivo Inhibition of MEK in Pancreatitis-Induced Tumors
Six-week-old KrasG12Dmice were treated to induce pancreatitis, as described
previously (Morris et al., 2010). On Day 1 postcerulein injection, mice received
a single daily dose of 25mg/kg BAY 86-9766 or vehicle by oral gavage, 6 days/
week for 3 weeks.
In Vivo Treatment of KrasG12D;p53KO Mice with Erlotinib
or Cetuximab
Seven-day-old KrasG12D;p53KO mice were injected i.p. with either cetuximab
(twice per week, 2 mg/kg), erlotinib (daily, 25 mg/kg), or vehicle (daily) for
3 weeks and sacrificed at 28 days of age. To assess efficacy of gemcitabine
alone and in combination with erlotinib, mice with detectable tumor burden
by MRI, determined by a clinical 1.5 T MRI device, were treated daily with
gemcitabine i.p. (120 mg/kg, four doses every third day) or gemcitabine i.p.
(100 mg/kg, four doses every third day) in combination with erlotinib (daily,
50 mg/kg) by oral gavage. Tumor burden was monitored by MRI. For acute er-
lotinib treatment, KrasG12Dwere treated with five daily doses of 250 mg/kg cer-
ulein, allowed to recover for 1 week, and then treated with 100 mg/kg erlotinib
12, 6, and 2 hr before sacrifice and tissue harvest.
Statistical Analysis
Statistical analyses were performed using the Mann–Whitney test for nonnor-
mally distributed, unpaired data. Tumor burden was compared between
strains using one-way analysis of variance. With all box plots, the bottom
and top of the box are the 25th and 75th percentile and the central line is
the median of the data. The whiskers represent maximum and minimum
values, with the remaining dots being outliers.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2012.07.024.
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